Moraxella Bacteremia in Cancer Patients

Shamra Zaman ¹, John Greene ²

1. Medicine, University of South Florida, Tampa, USA 2. Internal Medicine, Moffitt Cancer Center, Tampa, USA

Corresponding author: John Greene, john.greene@moffitt.org

Abstract

Moraxella is a gram-negative bacterium part of the *Moraxellaceae* family. It is a pathogen that is commonly found in the upper respiratory tract of humans. It is a rare cause of community-acquired pneumonia and can be found in immunocompromised individuals, especially those with impaired humoral immunity such as hypogammaglobulinemia and those with lung diseases.

We present three cases of *Moraxella* infections at the Moffitt Cancer Center between the years 2011 and 2017. We performed a literature review of *Moraxella* bacteremia in cancer patients and included three patients, two with a history of multiple myeloma and one undergoing radiation therapy for non-small cell lung carcinoma. None of the patients died as a result of the infection. *Moraxella* infections can result in a range of severity with increasing resistance to antibiotic therapy.

Categories: Infectious Disease, Oncology

Keywords: moraxella, myeloma, respiratory tract, pneumonia, immunocompromised patient

Introduction

Moraxella is a gram-negative bacterium that has a *coccobacillus* shape [1]. Originally considered normal flora in the human respiratory system, it can cause respiratory tract infections [2]. It primarily affects adults with prior chronic lung disease and the immunosuppressed. The most common immunodeficiency is hypogammaglobulinemia, which is found in patients with multiple myeloma and chronic lymphocytic leukemia (CLL). Invasive infections include meningitis, pneumonia, and endocarditis [3,4].

We present the cases of three cancer patients with *Moraxella* infections that illustrate the most common risk factors that predispose to this infection.

Case Presentation

Case 1

A 62-year-old Hispanic male presented with a fever and cough. He has a significant history of multiple myeloma and underwent an autologous stem cell transplant in 2007, four years prior to consultation. Prior infections included herpes zoster on the back and genital herpes. Eventually, the relapse of myeloma required chemotherapy complicated by neutropenia. His medical history consisted of hypertension, prostate hypertrophy, folliculitis on the scalp, hyperlipidemia, hemorrhoids, and kyphoplasties of the spine. He was hospitalized with pneumonia requiring a short hospitalization early in 2011. He had reported having one cat as a pet with no bites or scratches.

Upon physical examination, he presented with fever with a temperature of 100.9°F. The white blood cell count was 0.78 cells/uL with a neutrophil count was 460 cells/uL, immunoglobulin (Ig) G was 498 mg/dL, and IgA and IgM were undetectable. CT scan revealed maxillary polyps and maxillary sinusitis. CT also presented areas of consolidation (Figure 1). One of two peripheral blood cultures grew gram-negative *diplococci* bacteria subsequently identified as *Moraxella*, and the sputum culture grew *Candida*. The patient was initially treated with cefepime, tobramycin, and acyclovir. After improvement, he was discharged three days later and completed a seven-day course of oral levofloxacin.

Review began 05/11/2021

Review ended 05/20/2021

Published 05/29/2021

© Copyright 2021

Zaman et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

FIGURE 1: CT scan of the thorax showing the focal area of consolidation (red arrow)

Case 2

A 60-year-old African American female was diagnosed with lambda multiple myeloma and presented with renal insufficiency. Several months prior to admission, she was treated for sepsis and a pathological fracture of the right proximal femur and placed on lenalidomide. After beginning Revlimid®, she developed Steven-Johnson syndrome resulting in intubation in the intensive care unit. After recovery, she continued chemotherapy and became dependent on hemodialysis. She was again admitted for sepsis, and a new distal femur pathologic fracture was discovered the following year. Several months later, she was admitted to Moffitt Cancer Center, Tampa, Florida, from a rehabilitation facility for failure to thrive.

The white blood cell count was 3.9 K cells/uL, with a lymphocyte count at 1.5 cells/uL. IgA and IgM were undetectable. Chest X-ray, posterior-anterior and lateral, showed a moderate right pleural effusion and a left lateral sixth rib pleural-based mass (Figure 2). The bone survey showed multiple lucencies throughout the skeleton. CT scan of the chest demonstrated multiple osteolytic bone lesions, right humeral head fracture, and a moderate right pleural effusion with secondary right lung atelectasis. *Moraxella catarrhalis* bacteremia was found on two blood cultures.

FIGURE 2: Image showing X-ray of the chest

Right-sided pleural effusion (thin arrow) and left-sided pleural-based mass (thick arrow) can be seen.

She was treated with seven days of ceftriaxone. She recovered from this infection but died the following year from myeloma progression and renal failure.

Case 3

A 77-year-old female patient with a history of coronary artery disease, chronic obstructive pulmonary disease, and gastroesophageal reflux disease was diagnosed with non-small cell lung carcinoma and treated with radiation therapy. She had completed three of the five radiation treatments when she presented with abdominal pain and fever of 101.9°F that required hospitalization.

The white blood cell count was 13.45 cells K/uL. Physical findings included injection site cellulitis from intravenous Ig infusion. Blood cultures grew gram-negative rods identified as *Moraxella osloensis*. She was treated with intravenous cefepime. Five days after hospitalization, she improved and was discharged on oral ciprofloxacin for 14 days.

Discussion

Patients undergoing treatment for lung cancer, myeloma, and CLL are highly vulnerable to respiratory infections. *Moraxella* bacteremia may present with minimal respiratory symptoms and radiographic findings [5-7]. The most common genus includes *Moraxella catarrhalis*.

In this study, we illustrate the most common risk factors for *Moraxella* infections. All cases presented were immunosuppressed with a history of lung cancer or multiple myeloma that resulted in hypogammaglobulinemia. One of the patients had an invasive infection with *Moraxella osloensis*, a rare *Moraxella* species.

Moraxella is a pathogen that is susceptible to most beta-lactamase stable antibiotics and fluoroquinolones [8-11]. The choice of antimicrobial agents depends on the age of the patient, comorbid conditions, and

desired antimicrobial coverage [12]. All cases responded to beta-lactamase stable antibiotics and fluoroquinolones such as levofloxacin and ciprofloxacin. Hwang found 90% of *Moraxella catarrhalis* strains to be resistant to penicillin and amoxicillin due to the production of β -lactamases [13]. Another study in 2002 by Schmitz et al. found that 98% of *Moraxella* isolates produce beta-lactamases [14].

Conclusions

Moraxella infections develop in older adults who have structural lung diseases such as emphysema, chronic obstructive lung disease, and lung cancer. In addition, patients with humoral immunodeficiency due to hypogammaglobulinemia from multiple myeloma and CLL are especially vulnerable to respiratory infections that may result in bacteremia. *Moraxella* can cause invasive infection in some patients with minimal respiratory symptoms. Because of the frequent production of beta-lactamase, therapy with a beta-lactamase stable antibiotic or fluoroquinolone is preferred. The prognosis from infection is excellent, but the underlying malignancy and other comorbid conditions ultimately cause the patient's demise.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Augustyniak D, Seredyński R, McClean S, et al.: Virulence factors of *Moraxella catarrhalis* outer membrane vesicles are major targets for cross-reactive antibodies and have adapted during evolution. *Sci Rep*. 2018, 8:4955. [10.1038/s41598-018-23029-7](https://doi.org/10.1038/s41598-018-23029-7)
2. Karalus R, Campagnari A: *Moraxella catarrhalis*: a review of an important human mucosal pathogen. *Microbes Infect*. 2000, 2:547-59. [10.1016/s1286-4579\(00\)00314-2](https://doi.org/10.1016/s1286-4579(00)00314-2)
3. Correa-Martínez CL, Rauwolf KK, Schuler F, Füller M, Kampmeier S, Groll AH: *Moraxella nonliquefaciens* bloodstream infection and sepsis in a pediatric cancer patient: case report and literature review. *BMC Infect Dis*. 2019, 19:836. [10.1186/s12879-019-4489-y](https://doi.org/10.1186/s12879-019-4489-y)
4. LaCroce SJ, Wilson MN, Romanowski JE, Newman JD, Jhanji V, Shanks RMQ, Kowalski RP: *Moraxella nonliquefaciens* and *M. osloensis* are important *Moraxella* species that cause ocular infections. *Microorganisms*. 2019, 7:163. [10.3390/microorganisms7060163](https://doi.org/10.3390/microorganisms7060163)
5. Tan L, Grewal PS: Pathogenicity of *Moraxella osloensis*, a bacterium associated with the nematode *Phasmarhabditis hermaphrodita*, to the slug *Deroceras reticulatum*. *Appl Environ Microbiol*. 2001, 67:5010-6. [10.1128/AEM.67.11.5010-5016.2001](https://doi.org/10.1128/AEM.67.11.5010-5016.2001)
6. Sajani S, Gufran A, Rudrapathy P, et al.: Prevalence and resistance pattern of *Moraxella catarrhalis* causing respiratory tract infections in cancer patients. *JOUR*. 2019, 18:10.
7. Yacoub AT, Monta R, Quaiser S, Acevedo I, Greene J: Pneumococcal bacteremia in patients with cancer: a retrospective observational study, 2003-2013. *Infect Dis Clin Pract*. 2015, 23:263-6. [10.1097/IPC.0000000000000272](https://doi.org/10.1097/IPC.0000000000000272)
8. Tete SM, Bijl M, Sahota SS, Bos NA: Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma. *Front Immunol*. 2014, 5:257. [10.3389/fimmu.2014.00257](https://doi.org/10.3389/fimmu.2014.00257)
9. Raveendran S, Kumar G, Sivanandan RN, Dias M: *Moraxella catarrhalis*: a cause of concern with emerging resistance and presence of *bro* beta-lactamase gene—report from a tertiary care hospital in south India. *Int J Microbiol*. 2020, 2020:7316257. [10.1155/2020/7316257](https://doi.org/10.1155/2020/7316257)
10. Han XY, Tarrand JJ: *Moraxella osloensis* blood and catheter infections during anticancer chemotherapy: clinical and microbiologic studies of 10 cases. *Am J Clin Pathol*. 2004, 121:581-7. [10.1309/QBB3-AVCM-GWA3-K1XK](https://doi.org/10.1309/QBB3-AVCM-GWA3-K1XK)
11. Jorgensen JH, Doern GV, Maher LA, Howell AW, Redding JS: Antimicrobial resistance among respiratory isolates of *Haemophilus influenzae*, *Moraxella catarrhalis*, and *Streptococcus pneumoniae* in the United States. *Antimicrob Agents Chemother*. 1990, 34:2075-80. [10.1128/AAC.34.11.2075](https://doi.org/10.1128/AAC.34.11.2075)
12. Yeo SF, Livermore DM: Effect of inoculum size on the in-vitro susceptibility to beta-lactam antibiotics of *Moraxella catarrhalis* isolates of different beta-lactamase types. *J Med Microbiol*. 1994, 40:252-5. [10.1099/00222615-40-4-252](https://doi.org/10.1099/00222615-40-4-252)
13. Hwang PH: A 51-year-old woman with acute onset of facial pressure, rhinorrhea, and tooth pain: review of acute rhinosinusitis. *JAMA*. 2009, 301:1798-807. [10.1001/jama.2009.481](https://doi.org/10.1001/jama.2009.481)
14. Schmitz FJ, Beeck A, Perdikouli M, et al.: Production of *BRO* beta-lactamases and resistance to complement in European *Moraxella catarrhalis* isolates. *J Clin Microbiol*. 2002, 40:1546-8. [10.1128/jcm.40.4.1546-1548.2002](https://doi.org/10.1128/jcm.40.4.1546-1548.2002)